"At the same time, expanded coverage could also increase Medicaid drug spending and put pressure on overall state budgets." Glucagon-like peptide-1 (GLP-1) drugs mimic the GLP-1 hormone, which helps control insulin and blood sugar levels, decreases appetite and slows digestion of food
Instead, clinical judgment focuses on your pre-existing GI symptoms
At Cymbiotika, we believe these have no place in a wellness routine
Read the full clinical review on MedShr's Health Tech Hub: #PreventiveMedicine #HomeHealthTesting #Thriva #HealthTech #MedShr #HealthTechHub #DigitalHealth #LipidManagement #HbA1c #RemoteMonitoring #MedEd #FOAMed #ClinicalInnovation To view or add a comment, sign in While this outcome was clearly going to happen following the January 2026 update to FDA guidance on wellness devices, it is good to see that the FDA has officially closed the 2025 warning letter to Whoop regarding their blood pressure product
Hu JF, Song X, Zhong K, Zhao XK, Zhou FY, Xu RH, et al